Medicare reimbursement and prescribing hormone therapy for prostate cancer.
Nancy L
NL
Keating
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000191:economics* / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000191:economics* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D011307:Drug Prescriptions / Q000191:economics / Q000706:statistics & numerical data*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D017273:Goserelin / Q000191:economics / Q000627:therapeutic use; D006295:Health Resources / Q000706:statistics & numerical data; D006801:Humans; D016729:Leuprolide / Q000191:economics / Q000627:therapeutic use; D008297:Male; D006278:Medicare / Q000331:legislation & jurisprudence; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000191:economics; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics; D018426:SEER Program; D014481:United States
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide